SIA
GALT icon

Soltis Investment Advisors’s Galectin Therapeutics GALT Stock Holding History

Soltis Investment Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-140,750
Closed -$297K – 481
2025
Q2 		$297K Hold
140,750
– – 0.02% 324
2025
Q1 		$172K Hold
140,750
– – 0.02% 354
2024
Q4 		$182K Hold
140,750
– – 0.02% 357
2024
Q3 		$387K Buy
+140,750
New +$346K 0.04% 250

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Soltis Investment Advisors's GALT Position: Q3 2025 in Review

Soltis Investment Advisors sold out of Galectin Therapeutics (GALT) in Q3 2025, closing a stake of 140,750 shares — an estimated $297K sold.

Soltis Investment Advisors first reported a position in GALT in Q3 2024 and held it in 4 quarters. The position peaked at $387K in Q3 2024. 84 funds tracked by Wall St. Rank hold GALT as of Q3 2025.

  • Soltis Investment Advisors reported no remaining Galectin Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Soltis Investment Advisors sold 140,750 Galectin Therapeutics shares in Q3 2025, an estimated $297K.
  • Soltis Investment Advisors first reported a position in Galectin Therapeutics in Q3 2024 and held it in 4 quarters.
  • Soltis Investment Advisors's Galectin Therapeutics position peaked at $387K in Q3 2024.
  • 84 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2025.

Based on Soltis Investment Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.